Table 2. Treatment Patterns by Regimen and Line of Therapy.
| Regimen/Treatment | Line of Treatment | |||
|---|---|---|---|---|
| First, n (%) | Second, n (%) | Third, n (%) | Fourth, n (%) | |
| All treatments | 2111 (100) | 476 (100) | 175 (100) | 88 (100) |
| Monotherapy | 655 (31.0) | 245 (51.5) | 136 (77.7) | 70 (79.5) |
| Combination therapya | 1456 (69.0) | 231 (48.5) | 39 (22.3) | 18 (20.5) |
| Rituximab-based | 2031 (96.2) | 411 (86.3) | 141 (80.6) | 83 (94.3) |
| B-R | 830 (39.3) | 129 (27.1) | 14 (8) | 9 (10.2) |
| B-R + RM | 6 (0.3) | — | — | 1 (1.1) |
| Lenalidomide + R | 4 (0.2) | 7 (1.5) | 3 (1.7) | — |
| Idelalisib + R | — | — | 1 (0.6) | — |
| Yttrium + R | 4 (0.2) | 4 (0.8) | 3 (1.7) | — |
| R-CHOP | 426 (20.2) | 30 (6.3) | 6 (3.4) | 2 (2.3) |
| R-CHOP + RM | 1 (0.0) | — | — | — |
| R-CVP | 160 (7.6) | 41 (8.6) | 2 (1.1) | 3 (3.4) |
| R-CVP + RM | — | — | 1 (0.6) | — |
| RM | 396 (18.8) | 160 (33.6) | 99 (56.6) | 67 (76.1) |
| R-mono + maintenance | 204 (9.7) | 40 (8.4) | 12 (6.9) | 1 (1.1) |
| Non-rituximab-based | 80 (3.8) | 65 (13.7) | 34 (19.4) | 5 (5.7) |
| Bendamustine + obinutuzumab | 4 (0.2) | 6 (1.3) | 4 (2.3) | 2 (2.3) |
| CHOP | 15 (0.7) | 11 (2.3) | 3 (1.7) | 1 (1.1) |
| CVP | 6 (0.3) | 3 (0.6) | 2 (1.1) | — |
| Ibrutinib | 27 (1.3) | 17 (3.6) | 8 (4.6) | — |
| Lenalidomide | 24 (1.1) | 17 (3.6) | 10 (5.7) | — |
| Idelalisib | 4 (0.2) | 11 (2.3) | 7 (4) | 2 (2.3) |
Abbreviations: B-R, bendamustine + rituximab; CHOP, cyclophosphamide + vincristine + doxorubicin (either traditional or liposomal) + prednisone; CVP, cyclophosphamide + vincristine + prednisone; R, rituximab; RM, rituximab maintenance; R-mono, rituximab monotherapy.
aCombination therapies include bendamustine + R; bendamustine + R + RM; lenalidomide + R; idelalisib + R; yttrium + R; R-CHOP; R-CHOP + RM; R-CVP; R-CVP + RM; bendamustine + obinutuzumab; CHOP + CVP.